HARMONY Study: Pimavanserin Significantly Reduces Risk of Relapse of Dementia-Related Psychosis

Authors

• Erin P. Foff, ACADIA Pharmaceuticals Inc.
• Jeffrey L. Cummings, University of Nevada, Las VegasFollow
• Maria-Eugenia Soto-Martin, University Hospital of Toulouse
• Pierre Tariot, Banner Alzheimer's Institute
• Bradley McEvoy, ACADIA Pharaceuticals Inc.
• Srdjan Stankovic, ACADIA Pharmaceuticals Inc.

Document Type

Abstract

Publication Date

11-4-2020

Publication Title

International Psychogeriatrics

Volume

32

Issue

S1

First page number:

143

Last page number:

143

Keywords

Dementia-related psychosis (DRP); Azheimer's disease (AD); Parkinson's disease (PD); Dementia; Harmony study

Disciplines

Geriatrics | Gerontology | Medical Specialties | Medicine and Health Sciences | Social and Behavioral Sciences | Sociology

File Format

pdf

File Size

219 KB

Language

English

Rights

IN COPYRIGHT. For more information about this rights statement, please visit http://rightsstatements.org/vocab/InC/1.0/

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Repository Citation

Foff, E. P., Cummings, J. L., Soto-Martin, M., Tariot, P., McEvoy, B., Stankovic, S. (2020). HARMONY Study: Pimavanserin Significantly Reduces Risk of Relapse of Dementia-Related Psychosis. International Psychogeriatrics, 32(S1), 143-143.
http://dx.doi.org/10.1017/S104161022000280X